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Abstract
Background: We aimed to investigate prevalence and prognostic role of SOX2, PIK3CA, FGFR1 and BRF2 gene gain in
patients with surgically resected non-small cell lung cancer (NSCLC).
Methods: SOX2, PIK3CA, FGFR1 and BRF2 gene copy number was assessed by fluorescence in situ hybridization (FISH) in
arrayed tissue cores from 447 resected NSCLCs.
Results: Increased gene copy number (FISH+) for SOX2, PIK3CA, FGFR1 and BRF2 was observed in 23.6%, 29.2%, 16.6% and
14.9% of cases, respectively. FISH+ status for each gene was significantly associated with smoking history, squamous cell
carcinoma (SCC) histology, and increased copy number of the other studied genes. Multivariate analysis of overall survival
indicated increased SOX2 gene copy number (P= 0.008), stage I-II (P,0.001), and adenocarcinoma or SCC histology
(P= 0.016) as independent, favorable prognostic factors. A statistically significant interaction was observed between stage
and SOX2 gene status (P= 0.021), indicating that the prognostic impact of SOX2 gene gain differs across stages and is limited
to patients with stage I-II disease (HR 0.44, 95% CI: 0.25–0.77; P= 0.004, adjusted for histology).
Conclusions: Increased SOX2 gene copy number is an independent and favorable prognostic factor in surgically resected,
early stage NSCLC, regardless of histology. SOX2, PIK3CA, FGFR1 and BRF2 gene gains are likely to occur concurrently, with
potentially relevant implications for the development of new therapeutic strategies.
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Introduction
Lung cancer is the leading cause of cancer death worldwide and
survival rates are poor. In the last few years, progress in the
knowledge of lung cancer biology led to the identification of
activated oncogenes that can be therapeutically targeted by novel
agents. Among those are the tyrosine kinase inhibitors, such as
gefitinib and erlotinib for patients with Epidermal Growth Factor
Receptor (EGFR) mutations [1–2] and, more recently, crizotinib
for subjects with Anaplastic Lymphoma Kinase (ALK) rearrange-
ments [3]. These agents have significantly improved the outcome
of biologically selected non-small cell lung cancer (NSCLC)
patients with advanced disease, encouraging the identification of
novel therapeutic targets.
The SRY (sex determining region Y)-box 2 (SOX2) gene, located
on chromosome 3q26.33, encodes for a member of the SRY-
related HMG-box family of transcription factors and has been
implicated in pluripotency regulation in embryonic stem cells [4].
Upregulation of SOX2 induces cell proliferation and anchorage-
independent growth in lung squamous cell carcinoma (SCC) cell
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lines and drives lung tumorigenesis in mice [5-6]. Amplification of
SOX2 has been associated with lung SCC [5–8], with retrospective
data suggesting a trend for improved survival in favor of SOX2
gene gain in surgically resected patients [7–8].
The PIK3CA gene encodes for the catalytic subunit p110a of
class IA phosphatidylinositol 3-kinases (PI3K) and has been
identified to function as an oncogene in human malignancies
activated by gene amplification or mutations [9]. Importantly,
preclinical models showed that inhibition of the PI3K pathway
impairs survival of NSCLC cells harboring PIK3CA gene
alterations [10–11], and numerous novel PI3K, Akt and mTOR
inhibitors have entered clinical trial testing for the treatment of
PI3K-addicted cancers. PIK3CA is located on chromosome
3q26.32, close to the SOX2 locus. Comparative genomic
hybridization studies have shown distinct amplification levels for
SOX2 and PIK3CA in lung SCC with 3q26 gain [5], suggesting that
they might play independent oncogenic roles.
The fibroblast growth factor receptor 1 (FGFR1), which is
encoded by a gene located on chromosome 8p12.1, is a member of
a four tyrosine kinase receptor family (FGFR1–4) and has been
widely studied as a key receptor involved in embryonic develop-
ment [12]. Amplification of FGFR1 has been recently reported in
up to 22% of lung SCC [13] and has been associated with
sensitivity to FGFR1 tyrosine kinase inhibitors in multiple
preclinical models, including lung SCC cell lines [13–15], leading
to clinical trials of these agents in FGFR1-amplified tumors.
The B-related factor 2 (BRF2) gene, located on chromosome
8p11.23 very close to FGFR1, encodes a subunit of RNA
polymerase III (Pol III) transcription initiation complex, which is
responsible for the transcription of a number of noncoding RNA
genes whose products are involved in protein synthesis, RNA
processing and transcription [16]. The RNA pol III is often
deregulated in cancer, and BRF2 was recently identified as a novel
oncogene in lung SCC activated by increased copy number [17].
In fact, BRF2 amplification determines an increased RNA Pol III
activity and sustained cell proliferation and survival in vitro [17].
Alterations in copy number of the SOX2, PIK3CA, FGFR1 and
BRF2 genes have been individually studied in a number of
NSCLC populations, particularly in lung SCC, with limited and
sometimes conflicting data regarding their prognostic impact.
Moreover, the prevalence of copy number gains of more than one
gene and its effect on patient survival is still largely unexplored.
The present study was conducted to investigate the prevalence of
SOX2, PIK3CA, FGFR1 and BRF2 gene copy number changes in a
large, unselected cohort of surgically resected NSCLC patients, to
verify concurrent genomic gains, and to determine whether copy
number alterations in these genes affect patient outcome.
Patients and Methods
Ethics Statement
Institutional Review Board (IRB) approval (#304/12) was
obtained from the Istituto Clinico Humanitas ethical committee.
Written informed consent was obtained from patients undergoing
active follow up at our institution. IRB waived the requirements
for written informed consent from patients that could not be
reached. The study was conducted in accordance with ethical
principles stated in the most recent version of the Declaration of
Helsinki.
Patients
This retrospective study was conducted in a previously reported
cohort of 447 Caucasian NSCLC patients that received a radical
resection of a primary NSCLC between 2000 and 2004 at Istituto
Clinico Humanitas (Rozzano, Italy) [18]. A tissue microarray
(TMA) was constructed using 0.6 mm diameter cores.
Fluorescence In Situ Hybridization (FISH) Analysis
The Bacterial Artificial Chromosome (BAC) clones RP11-
459K06, RP11-245C23, RP11-168H08 and RP11-350N15,
respectively containing human DNA inserts from regions homol-
ogous to SOX2, PIK3CA, BFR2 and FGFR1, were used for the
enumeration FISH probes, according to previously described
protocols [19–20]. Copy number per cell for each gene was
enumerated on at least 50 tumor cells from 2 tissue cores per
patient by an expert cytogeneticist blinded to patient data. In
absence of validated FISH scoring criteria for these genes, a pre-
specified cut-off of mean $4 gene copies/cell, previously used to
define gene gain with other techniques [13], or presence of gene
clusters indicating true gene amplification, was set to identify cases
with increased gene copy number (FISH+). Examples of FISH
patterns are shown in figure 1.
Statistical Analysis
Associations between demographical and clinical characteristics
and FISH status were estimated using the continuity adjusted Chi-
square or the Fisher exact test, when appropriate. Pearson
correlation coefficient was used to test the correlation between
FISH status of each gene.
Overall survival (OS), calculated from the time of diagnosis to
patient death or last contact, was evaluated using the Kaplan–
Meier method. Differences between groups were evaluated by
using log rank test. Hazard ratios with their corresponding 95%
confidence intervals (95% CI) were calculated using the Cox
proportional hazards regression model. Statistical significance was
set at ,0.05 for each analysis. All statistical analyses were carried
out using R package.
Results
Patient Characteristics
The study included a cohort of 447 patients with surgically
resected NSCLC. Details of the cohort have been previously
described [18] and patient characteristics are summarized in
table 1. Briefly, the majority of patients were male (82.8%), former
(53.2%) or current smokers (36.0%), with histological grade 1 or 2
tumors (64.2%). All patients underwent radical surgery and tumors
were staged according to the TNM classification with evidence of
pathological stage I in 37.1% of cases, stage II in 22.1%, stage III
in 32.7% and stage IV in 8.1%. The latter group included patients
with a solitary metastatic lesion, mostly in the brain or adrenal
glands, amenable of surgery or stereotactic radiosurgery. Patients
with stage III pN2 disease (n = 101) received mediastinal post-
operative radiotherapy. Overall, given the surgical timeframe
(2000–2004), no patients with stage I-II tumors received post-
operative systemic treatment, while only 18 subjects with stage III
disease were treated with adjuvant platinum-based chemotherapy.
The majority of patients were diagnosed with adenocarcinoma
(54.6%), while 138 (30.9%) and 65 (14.5%) patients had SCC or
other histology, respectively. After a median follow up of 60.4
months, 244 deaths occurred and median survival was 42.5
months. Significantly longer survival was observed for patients
with stage I–II (herein referred to as ‘‘early stage’’) tumors when
compared with those with stage III–IV disease (P,0.001). Patients
with SCC or adenocarcinoma had similar outcome and lived
longer than patients with other histologies (P,0.001). No survival
difference was observed according to gender, smoking history or
pathological grade.
SOX2 Gene Gain in NSCLC
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e95303
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SOX2 and PIK3CA gene status was successfully determined in
445 (99.6%) and 435 (97.3%) patients, respectively. Overall, SOX2
increased gene copy number was detected in 105 cases (23.6%),
with true gene amplification observed in 19 patients (4.3%).
PIK3CA gene gain was found in 29.2% of patients, including 21
cases (4.8%) with true gene amplification. As expected given their
physical proximity, a statistically significant association was
observed for copy number gain between SOX2 and PIK3CA
(Pearson correlation coefficient: 0.78, P,0.001), with discordant
FISH results between the two genes in only 9.9% of cases. This
association was maintained across all histological subtypes (data
not shown). As summarized in table 2, both SOX2+ and PIK3CA+
status significantly associated with male gender, former/current
smoking history, and SCC histology. Additionally, PIK3CA gene
gain was more commonly observed in grade III tumors
(P=0.040). All cases with SOX2 true gene amplification were
SCC, for an overall prevalence of 13.8% SOX2-amplified tumors
in patients with SCC histology. Similarly, PIK3CA true gene
amplification was found in 12.8% of cases with SCC, while only 4
patients with non-squamous tumors were PIK3CA-amplified,
including 3 adenocarcinomas and one pleomorphic carcinoma.
SOX2+ patients had a significantly longer survival than SOX2-
subjects (53.7% vs 41.1% 5-year OS, P=0.019) (figure 2A), with
no difference in outcome between cases with $4 mean gene
copies/cell and those with true gene amplification (P=0.937).
Subgroup analyses according to single clinico-pathological char-
acteristics, including stage, histology, sex, smoking status and
grade, detected a significant survival advantage for SOX2+ patients
in the subset of early stage (70.4% vs 51.8% 5-year OS, P=0.004,
figure 2B) and grade 3 tumors (52.3% vs 37.4% 5-year OS,
P=0.037). In patients with stage III–IV disease, no survival
difference was detected between SOX2+ and SOX2- cases
(P=0.993), while a trend for a better outcome in favor of
SOX2+ subjects was observed in the SCC subgroup (P=0.053).
Survival data according to PIK3CA gene status were similar to
SOX2, likely as a result of the substantial overlap between the
FISH status of these two genes. In fact, a statistically significant
survival advantage was observed for PIK3CA+ patients when
compared with PIK3CA- patients in the whole population (52.2%
vs. 40.9% 5-year OS, P=0.044) (figure 2C). The survival
advantage for PIK3CA+ patients remained statistically significant
only in the subset of early stage tumors (69.5% vs 51.5% 5-year
OS, P=0.005), with a trend for improved survival in patients with
SCC (P=0.064).
We further aimed to explore the survival patterns of patients
with discordant SOX2/PIK3CA gene status (n = 43). As shown in
figure 2D, there was similar outcome between SOX2-/PIK3CA+
(n = 34) and double negative (n = 297) patients, while survival of
SOX2+/PIK3CA- individuals (n = 9) appeared to be similar to that
of the double positive group (n= 93).Those findings suggested that
PIK3CA gene gain was not per se prognostically relevant.
FGFR1 and BRF2 Copy Number Gain
A total of 445 (99.6%) patients were assessable for FGFR1 gene
copy number, with 16.6% FISH+ patients, including 37 cases
(8.3%) with true gene amplification. FGFR1 gene gain was
significantly more common in patients with SCC than in those
with adenocarcinoma or other histologies (SCC vs non-SCC:
28.3% vs 11.4%, P,0.001,) while no association with gender,
Figure 1. Specimen B5b showing gene amplification for FGFR1 (A, red) and BRF2 (B, green) and low copy number for SOX2 (A, gold),
and PIK3CA (B, red); specimen C4d showing gene amplification for SOX2 (C, gold) and PIK3CA (D, red) and low copy number for
FGFR1 (C, red) and BRF2 (D, green).
doi:10.1371/journal.pone.0095303.g001
Table 1. Patient characteristics.
Characteristics n %a
Total 447 100
Sex
Male 370 82.8
Female 77 17.2
Smoking history
Never 40 8.9
Former 238 53.2
Current 161 36.0
Unknown 8 1.8
Histology
Adenocarcinoma 244 54.6
SCC 138 30.9
Other 65 14.5
Stage
I 166 37.1
II 99 22.1
III 146 32.7
IV 36 8.1
Grade
I 32 7.2
II 255 57.0
III 158 35.3
Not reported 2 0.4
apercentages have been rounded and may not total 100%.
Abbreviation: SCC= squamous cell carcinoma.
doi:10.1371/journal.pone.0095303.t001
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smoking status, stage or grade was found (table 2). FGFR1 true
gene amplification occurred in 17.4% of SCC but was also
observed in 3/26 (11.5%) tumors with neuroendocrine differen-
tiation and 2/28 (7.1%) never-smokers with lung adenocarcinoma,
including a female with a concurrent EGFR L858R mutation.
BRF2 gene status was evaluated by FISH in 435 (97.3%)
patients and increased gene copy number was observed in 14.9%
of cases, including 27 patients (6.2%) with gene amplification. As
shown in table 2, former/current smoking history and SCC
histology were significantly associated with BRF2+ status. Likely in
consequence of their close physical location on chromosome 8p11-
12, a significant association was observed between FGFR1 and
BRF2 gene copy number (Pearson correlation coefficient: 0.78,
P,0.001), with only 5.3% of cases with discordant FISH results.
The association between the two genes was independent of
histology (data not shown). Furthermore, significant associations
were observed between copy number gains of genes located on
different chromosomes (FGFR1 or BRF2 with SOX2 or PIK3CA,
P,0.001 for each association), regardless of histology. Particularly,
SOX2 and PIK3CA gene gains were observed in 55.4% and 75.7%,
respectively, of FGFR1+ tumors.
The FGFR1+ or BRF2+ patients survived longer than those with
no or low copy number gain, although this difference did not
reach statistical significance (FGFR1, P=0.324; BRF2, P=0.179)
(figures 2E and 2F). FGFR1 gene copy number failed to show a
significant prognostic impact when analysing survival according to
clinico-pathological characteristics, including sex, smoking status,
stage, histology and grade (data not shown). Conversely, a
significant survival advantage was observed for BRF2+ patients
with early stage disease when compared with the BRF2- group
(74.6% vs 54.0% 5-year OS, P=0.040), while no prognostic
relevance was observed for BRF2 gene copy number in other
patient subsets (data not shown). Due to the substantial overlap
between FGFR1 and BRF2 FISH status, no survival differences
were found in the whole population when grouping patients
according to both genes (data not shown). Similarly, no survival
impact was observed when combining FGFR1 or BRF2 with SOX2
or PIK3CA FISH results in the whole population or in clinically-
defined subgroups (data not shown).
Multivariate Analysis
As previously mentioned, factors associated with survival were
stage, histology, SOX2 and PIK3CA gene copy number. Consid-
ering the strong association between SOX2 and PIK3CA gene
status, the two genes were assessed in two separate models. In the
SOX2 model, SOX2 gene gain, early stage and adenocarcinoma/
SCC histology emerged as independent prognostic factors for
improved survival (HRSOX2+ vs SOX2- 0.48, 95% CI: 0.28–0.83,
P=0.008; HRstage I-II vs III-IV 0.49, 95% CI: 0.37–0.65; P,0.001;
HR adenocarcinoma/SCC vs other 0.67, 95% CI: 0.46-0.93; P=0.016).
Importantly, a statistically significant interaction was observed
between stage and SOX2 gene status (P=0.021), indicating that
the prognostic impact of increased SOX2 gene copy number
differed according to tumor stage and was limited to patients with
early stage disease (HR 0.44, 95% CI: 0.25–0.77; P=0.004,
adjusted for histology). In contrast, in the multivariate model
considering PIK3CA gene copy number, stage and histology,
PIK3CA gene gain failed to predict a significant longer survival
(P=0.135).
Table 2. Associations between FISH status and patient characteristics.
SOX2 PIK3CA FGFR1 BRF2
(N=445) (N=435) (N=445) (N=435)
2 + 2 + 2 + 2 +
n % n % P value n % n % P value n % n % P value n % n % P value
Total 340 76.4 105 23.6 308 70.8 127 29.2 371 83.4 74 16.6 370 85.1 65 14.9
Sex
Male 273 74.0 96 26.0 0.012 243 67.7 116 32.3 0.003 305 82.7 64 17.3 0.469 300 83.6 59 16.4 0.085
Female 67 88.2 9 11.8 65 85.5 11 14.5 66 86.8 10 13.2 70 92.1 6 7.9
Smoking History
Never 37 92.5 3 7.5 0.010 35 89.7 4 10.3 0.005 37 92.5 3 7.5 0.121 38 97.4 1 2.6 0.018
Former + Current 296 74.4 102 25.6 265 68.3 123 31.7 327 82.2 71 17.8 324 83.5 64 16.5
Histology
SCC 69 50.0 69 50.0 ,0.001a 55 41.3 78 58.7 ,0.001a 99 71.7 39 28.3 ,0.001a 95 71.4 38 28.6 ,0.001a
Adenocarcinoma 217 89.3 26 10.7 199 84.0 38 16.0 215 88.5 28 11.5 215 90.3 23 9.7
Other 54 84.4 10 15.6 54 83.1 11 16.9 57 89.1 7 10.9 60 93.8 4 6.2
Stage
I–II 200 75.5 65 24.5 0.654 179 69.4 79 30.6 0.495 222 83.8 43 16.2 0.883 221 85.7 37 14.3 0.773
III–IV 140 77.8 40 22.2 129 72.9 48 27.1 149 82.8 31 17.2 149 84.2 28 15.8
Grade
I–II 226 79.0 60 21.0 0.089 207 74.2 72 25.8 0.040 241 84.3 45 15.7 0.545 239 85.4 41 14.6 0.881
III 112 71.3 45 28.7 99 64.3 55 35.7 128 81.5 29 18.5 129 84.3 24 15.7
aSCC vs non-squamous histology.
Abbreviation: SCC= squamous cell carcinoma.
doi:10.1371/journal.pone.0095303.t002
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The survival impact observed for BRF2 gene gain in patients
with early stage disease was not confirmed in the multivariate
model after correction for histology (P=0.135), although the small
number of BRF2+ cases precluded robust conclusions.
Discussion
This study evaluated the prognostic relevance of copy number
alterations of four oncogenes previously associated with lung SCC
- SOX2, PIK3CA, FGFR1 and BRF2 - in a large cohort of surgically
resected NSCLC patients. For the first time, we report increased
SOX2 gene copy number assessed by FISH as an independent
favorable prognostic factor in patients with stage I and II NSCLC,
regardless of histology.
SOX2, a transcription factor that plays a key role in embryonic
development, has recently emerged as an attractive therapeutic
target in lung cancer. In fact, amplification and/or overexpression
of SOX2 have been reported in lung SCC, lung adenocarcinoma
and, more recently, small-cell lung cancer [5,20–21]. Preclinical
reports have been consistent in showing that SOX2 silencing leads
to significant impairment of cell growth in lung cancer models,
supporting SOX2 inhibition as a promising anticancer strategy in
lung malignancies [5,22].
Defining FISH+ status as mean$4 gene copies/cell or presence
gene clusters (true gene amplification), SOX2 gene gain was
observed in about one fourth of NSCLCs and was significantly
associated with male gender, exposure to tobacco smoke and SCC
histology, as previously reported by others [5–7]. Particularly, half
of lung SCC categorized as FISH+, with true gene amplification
occurring in 13.8% of cases, while lung adenocarcinomas
presented increased SOX2 gene copy number in 10.7% of samples
with no cases harbouring true gene amplification. These findings
are roughly in line with other FISH studies in NSCLC, in which
different scoring criteria were used [7–8].
The prognostic role of SOX2 has been investigated in
retrospective NSCLC series. Despite data from a recent meta-
analysis suggesting a favorable prognostic impact for SOX2
expression in NSCLC regardless of histology,[23] most studies
showed that SOX2 protein overexpression predicted prolonged
survival in surgically resected lung SCC [7–8], while its survival
impact in lung adenocarcinoma remains controversial [21,24].
Two studies have shown a significant association between SOX2
protein expression evaluated by immunohistochemistry and SOX2
gene gain assessed by FISH, and suggested a favorable prognostic
role for increased SOX2 gene copy number in lung SCC, although
statistical significance was not reached [7–8]. Particularly,
Wilbertz et al. detected a trend for improved survival in lung
SCC patients with $10 SOX2 copies/cell compared with tumors
with no or low level amplification, but this effect was lost in the
multivariate model [7].
For the first time, we reported a statistically significantly
improved overall survival for SOX2 FISH+ patients with stage I
and II NSCLC. Importantly, the favorable prognostic effect of
SOX2 gene gain observed in our study, where non-SCC patients
accounted for about 38% of SOX2+ cases, was independent of
histology and PIK3CA gene gain. Our findings contrast with those
of another study where a negative survival impact for SOX2 low
level amplification, compared to lack of amplification, was
observed in lung adenocarcinoma [7]. Additionally, our data
indicate that the survival benefit observed in unselected early stage
NSCLC was not limited to patients with true gene amplification,
but was also extended to those with mean $4 SOX2copies/cell
and no gene clusters. The discrepancies between our study and
that of Wilbertz et al. might be explained by differences in FISH
scoring criteria and patient clinical characteristics. The reason for
the lack of a survival impact for SOX2 gene gain in patients with
stage III and IV disease in our cohort is unclear and should be
further investigated. We speculate that SOX2 gene gain is an early
event in lung tumorigenesis and that tumor progression leads to
additional molecular abnormalities that affect patient outcome.
FGFR1 has recently emerged as a promising target in NSCLC
after the gene was reported as amplified in about 20% of lung
SCC [13–14,25], leading to early phase clinical trials of anti-
FGFR1 agents in FGFR1-amplified NSCLC. Our data confirmed
the previously reported association between increased FGFR1 gene
copy number and SCC histology. Importantly, FGFR1 gene gain
was also found in 11.4% of non-squamous tumors, including true
gene amplification in about 7% of adenocarcinoma patients with
never smoking history - the same population with an increased
likelihood of harboring EGFR mutations or ALK rearrangements -
and 11% among neuroendocrine tumors. Although the small
numbers of these subgroups preclude any firm conclusion, our
data suggest that FGFR1 gene copy number assessment should be
pursued in selected patients with non-squamous tumors to identify
candidates for anti-FGFR1 agents.
In the present study, we observed that concurrent copy number
gains of SOX2, PIK3CA, FGFR1 or BRF2 were common. While the
strong correlation between SOX2 and PIK3CA and between
FGFR1 and BRF2 gene status was anticipated because of their
proximity on chromosomes 3q26 and 8p11-12, respectively, our
study is the first to report statistically significant associations
between copy number gains in both genomic regions, regardless of
histology. In contrast, Weiss et al. described that FGFR1 and SOX2
amplifications were mutually exclusive in lung SCC, although in
that study the genomic gain was investigated by single-nucleotide
polymorphism arrays and different thresholds for copy number
changes were used [13]. Our findings should raise caution in the
development of PI3K or FGFR1 inhibitors as single agents in
NSCLCs with PIK3CA or FGFR1 gene gain, respectively. In fact,
in presence of concurrent genomic gain of multiple oncogenes
concomitant inhibition of more than one target could be required
to effectively impair tumor growth. This concept is supported by
the observation that PI3K inactivation with RNA interference
technology, in lung SCC cell lines with 3q26 amplification,
produced only limited effects on cell proliferation as opposed to
SOX2 knockdown [5]. Moreover, an intriguing observation was
the coexistence of FGFR1 true gene amplification and EGFR
L858R mutation in a female, never smoker patient with lung
adenocarcinoma, suggesting that some NSCLCs could be co-
dependent on FGFR1 and EGFR for survival. Overall, these data
suggest that in some tumors the assessment of a single drug target
may not be sufficient to predict drug sensitivity, addressing the
need for a deeper understanding of NSCLC biology.
Our study showed no statistically significant prognostic role for
FGFR1 or BRF2 gene copy number in surgically resected NSCLC
patients when using our predefined FISH scoring criteria,
although a trend for improved survival for FGFR1+ or BRF2+
patients could be observed in the whole population. Other
investigators have recently explored whether FGFR1 gene gain
affects survival in NSCLC with inconclusive results [13,26–29]. In
Figure 2. Kaplan-Meier overall survival estimates according to gene copy number. (A) SOX2, whole cohort. (B) SOX2, stage I-II. (C) PIK3CA,
whole cohort. (D) SOX2/PIK3CA, whole cohort. (E) FGFR1, whole cohort. (F) BRF2, whole cohort. Abbreviations: OS =overall survival; NR= not reached.
doi:10.1371/journal.pone.0095303.g002
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fact, while some authors reported a survival advantage for
NSCLCs with increased FGFR1 gene copy number [28], a recent
Korean study showed that FGFR1 high level amplification
negatively affects survival in surgically resected lung SCC [27].
Different techniques, scoring methods, and criteria for patient
selection (i.e. histology, ethnicity, stage, perioperative treatments)
might account for the differences observed across studies,
encouraging the assessment of the prognostic role of FGFR1 gene
copy number in uniformly selected cohorts.
In conclusion, we showed for the first time that increased SOX2
gene copy number is significantly associated with improved
survival in surgically resected stage I and II NSCLC patients,
regardless of histology. We also found that SOX2 gene gain is
associated with copy number gains of other actionable oncogenes,
including FGFR1 and PIK3CA. Our findings confirm the
complexity of NSCLC biology and encourage the exploration of
novel therapeutic combinations.
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